The burden of progressive fibrotic interstitial lung disease across the UK.

Simpson, Thomas; Barratt, Shaney L; Beirne, Paul; Chaudhuri, Nazia; Crawshaw, Anjali; Crowley, Louise E; Fletcher, Sophie; Gibbons, Michael A; Hallchurch, Philippa; Horgan, Laura; Jakaityte, Ieva; Lewis, Thomas; McLellan, Tom; Myall, Katherine J; Miller, Ryan; Smith, David J F; Stanel, Stefan; Thillai, Muhunthan; Thompson, Fiona; Wallis, Timothy; Wu, Zhe; Molyneaux, Philip L; West, Alex G

Abstract

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

Citation

Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021

Type

Article